- Featured Highlights Press Press ReleasesVaccine exclusively delivered with the PharmaJet Stratis® Needle-free Injection System December 13, 2022 11:00 AM Eastern Standard Time GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, a company that engineers precision delivery systems that overcomeRead more
ITI Receives FDA Fast Track Designation for ITI-3000
Featured Highlights Press Press ReleasesNovember 08, 2022 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announcedRead moreITI Announces Presentation on Nucleic Acid-Based UNITE® Vaccine Platform at Vaccines Summit 2022
Featured Highlights Press Press ReleasesOctober 10, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced todayRead more- Events Featured Highlights Past EventsBrian Stamper, VP Cell Therapy Operations will participate in the Endpoints webinar titled “Overcoming Manufacturing Challenges for Advanced Medicines” on November 1st from 12-1pm EST. Click here to register: https://webinars.endpts.com/overcoming-manufacturing-challenges-for-advanced-medicines/Read more
JP Morgan Annual Health Care Conference, Jan. 9-11, 2023, San Francisco, CA
Events Past EventsITI will be attending The 41st Annual Health Care Conference that will take place on January 9-11, 2023 at the Westin St. Francis in San Francisco, CA. This premier conferenceRead moreITI Announces the Appointment of Frances Harrison as Sr. VP, Regulatory Affairs
Featured Highlights Press Press ReleasesImmunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs September 06, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”),Read more- Featured Highlights Press Press ReleasesImmunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma -Top line data expected in second half ofRead more
Stashe Strong Annual Fundraiser, October 21, New York
Events Past Eventshttps://www.stachestrong.org/ Friday, October 21st Annual Fundraiser in NYC StacheStrong is a 501(c)3 non-profit devoted to raising funds and awareness for brain cancer research. Defeating brain cancer and improving the qualityRead moreVaccines Summit 2022, Washington, DC, Oct. 11-13, 2022
Events Past EventsVaccines Summit-2022 October 11-13, 2022 in Washington DC Organized around the theme “next-generation vaccines treatment and diagnostics that save lives”, Vaccines Summit-2022 is comprised of various sessions designed to offer comprehensive symposiumsRead moreBioBuzz Interview with Brian Stamper, ITI’s VP of Cell Therapy
Articles Blog Featured Highlights Presshttps://biobuzz.io/brian-stamper-appointed-vice-president-cell-therapy-operations-at-immunomic-therapeutics/Read moreImmunomic Therapeutics Appoints Vice President, Cell Therapy
Featured Highlights Press Press ReleasesJune 07, 2022 10:24 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleicRead moreITI Highlighted as Life Sciences Leader in Montgomery County, MD
Articles Blog PressImmunomic Therapeutics highlighted in Washington Business Journal as a life sciences leader in Maryland’s Montgomery County: The Immunology Capital Next to the Nation’s Capital. Click here to read more: http://ow.ly/NQrc50IVzkTRead more